Maze Therapeutics (MAZE) Capital Expenditures (2024 - 2026)

Maze Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at $93000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 68.9% year-over-year to $93000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $588000.0 (down 49.61% YoY) and the FY2025 annual result came in at $794000.0, down 30.78% from the prior year.
• Capital Expenditures slipped to $93000.0 in Q1 2026 per MAZE's latest filing, from $760000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $939000.0 in Q4 2024 and troughed at -$658000.0 in Q3 2025.
• A 3-year average of $226000.0 and a median of $279000.0 in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 259.11% in 2025, down 473.86% in 2025.
• Over 3 years, Capital Expenditures stood at $939000.0 in 2024, then decreased by 19.06% to $760000.0 in 2025, then plunged by 87.76% to $93000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $93000.0, $760000.0, and -$658000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.